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1. Introduction
Primary bone neoplasms are relatively uncommon. Among these tumors, 
osteosarcoma is the most common bone sarcoma, comprising approximately 35% 
of all malignant bone tumors [1]. Osteosarcoma affects approximately 500 chil-
dren and adolescents annually in the United States with incidence peaking in the 
second decade of life during periods of rapid bone turnover and growth spurts [2]. 
Osteosarcoma arises from sites of rapid bone turnover, making the distal femur, 
proximal tibia and proximal humerus the most typical locations [3].
Although a genetic predisposition with mutations in various tumor-suppressor 
genes incurs a higher likelihood of developing osteosarcoma, most cases of osteo-
sarcoma are sporadic. These chromosomal abnormalities yield defects in proteins 
involved in cell cycle regulation, resulting in uncontrolled cell proliferation [4]. 
These mutations are seen in a variety of disorders including Li-Fraumeni syndrome, 
which involves the p53 gene, or retinoblastoma, which involves the RB1 gene [5]. 
Some existing bone diseases such as Paget disease, fibrous dysplasia, enchon-
dromatosis, and hereditary multiple exostosis in addition to environmental risk 
factors, including radiation, have been identified as contributors to developing 
osteosarcoma.
Osteosarcoma serves as a broad term used to envelop the several different types 
of osteosarcoma that exist. These subtypes distinguish themselves through both 
clinical appearance as well as behavior. Unfortunately, the histological pictures 
of bone tumors do not definitively differentiate between osteogenic sarcoma, 
benign tumors, or other malignancies of bone [6]. Therefore, incorporation of both 
radiological and clinical tools is required to make the final diagnosis of osteogenic 
sarcoma [7].
In the setting of osteosarcoma, advanced imaging is warranted to evaluate the 
extent of tumor invasion, neurovascular involvement, bone marrow replacement, 
and presence of discontinuous metastases. Combination of MRI and CT imaging 
are helpful in demonstrating both soft tissue parameters of the tumor as well as cor-
tical integrity and the presence of pathologic fracture [8, 9]. New focus on advanced 
techniques in medical image processing for the detection and analysis of osteosar-
coma aims to better evaluate tumor locations, size, infiltrations of surrounding 
tissues, and identify the presence of satellite metastasis. Current research work 
utilizes positron emission tomography (PET) combined with MRI volumetry to 
better assess histological responses in bone sarcoma afflicted individuals, yielding 
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improvements in classification accuracy compared single modality evaluation [10]. 
The coupling of FDG-PET and MRI volumes offers improved prognostic and 
predicting capabilities for assessing the aggressiveness of tumors and aiding earlier 
clinical decisions regarding the utility of treatment options for patients.
A multidisciplinary approach is used for the treatment of patients with osteosar-
coma, offering survival rates of greater than 70% with metastatic disease [11, 12]. 
For high-grade osteosarcoma, treatment involves preoperative chemotherapy, wide 
surgical resection, and postoperative chemotherapy. Intratumor heterogeneity, 
a resultant of tumor evolution, is the fundamental challenge in cancer medicine. 
From heterogeneity stems disease relapse, metastatic behaviors, and drug resis-
tance [13]. Recent studies of cancer stem cells report a metabolism pathway that 
is predominantly through oxidative phosphorylation rather than glycolysis [14]. 
Targeting this metabolic pathway presents a potential therapeutic option against 
tumor cells. Within the mitochondria, a “two metabolic hit” theory has been 
proposed to utilize the synergistic effects of combining oxidative phosphorylation 
inhibition with c-Myc inhibition, which target both the oxidative phosphorylation-
dominant cancer stem cells and glycolysis-dominant non-cancer stem cells [15]. 
Novel compounds such as pterostilbene and honokiol have emerged as dual 
metabolic inhibition compounds that may lead to improvements in osteosarcoma 
prognosis, especially in the setting of metastatic disease [16].
Additional studies have shown that molecules belonging to the non-protein 
coding transcriptome may play essential roles in biological processes [17]. These 
non-protein coding RNAs are involved in gene expression regulation and have 
been found to play an important role in cancer development, progression, and 
chemoresistance of different tumors, including osteosarcoma [18]. Non-coding 
RNAs have emerged as potential prognostic biomarkers and therapeutic targets, 
being involved in cell signal transduction pathways, cell cycle and death regulation, 
chromatin remodeling, and gene expression regulation at both transcriptional and 
posttranscriptional levels [19]. Several tumors, such as urothelial carcinoma, colon 
carcinoma, and hepatocellular carcinoma have exhibited aberrant expression of 
non-coding RNAs, suggesting a new means of observation that may be exploited for 
diagnostic, prognostic preventative, or therapeutic processes [20]. A large number 
of long non-coding chain RNAs (lncRNAs) with oncogenic or tumor suppressive 
activity are differentially expressed in osteosarcoma. MALAT-1 (metastasis-
associated lung adenocarcinoma transcript 1), a lncRNA involved in recruiting 
mRNA splicing factors to transcription sites, is overexpressed in osteosarcoma and 
has expression levels linked to tumor metastatic potential [21]. The identification of 
lncRNAs serves as a catalyst for further research validating lncRNAs as prognostic 
and predictive biomarkers, therapeutic targets, and structural models for future 
mimicking pharmaceutical agents.
New targetable compounds generate hope for novel osteosarcoma treatment 
regimens, specifically with the affected pediatric population where chemotherapy 
has become the mainstay of treatment. Surgical resection yielded a high frequency 
of relapse and metastasis for children with osteosarcoma, shifting the focus to 
intense chemotherapy [22]. Similar to the discovery of lncRNAs, new molecular 
biologic factors that determine sensitivity to chemotherapy, invasive and metastatic 
potential of the tumor, and the prognosis of the disease have been elucidated in 
recent pediatric osteosarcoma research. Expression of methylguanine methyltrans-
ferase (MGMT) as well as MGMT methylation is correlated with poor histological 
response in osteosarcoma patients undergoing cisplatin treatment [23]. Other 
molecular factors such as vascular endothelial growth factor (VEGF) and c-Myc are 
under intense focus for characterizing tumor behavior, response to treatment, and 
dictating further treatment protocols [24]. Although there is significant relapse and 
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refractory rates for children diagnosed with metastatic osteosarcoma, comprehen-
sive assessments of these markers for histological response to chemotherapy may 
enhance current treatment protocols and guide future regimens.
Emphasis on basic science research remains a prime avenue for uncovering 
molecular mechanisms and biologic pathways that may lead to additional targeted 
therapies, less-toxic agents, and improved long-term survival in osteosarcoma [25]. 
Molecular biomarkers such as non-coding RNAs and cell-cycle regulator proteins 
are an area of current interest for the development of sensitive screening modalities 
as well as target-selective chemotherapeutic drugs. Progress in combined advanced 
imaging techniques offer better, non-invasive means for evaluating tumor, size, 
location and behavior, which facilitates clinical decision making. Treatment of 
osteosarcoma, an aggressive and malignant tumor, requires a multidisciplinary 
approach that incorporates progressive basic science research at all levels of care 
including diagnosis, treatment, and surveillance.
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